ATE421881T1 - Nkt-zellenaktivatoren, die alpha-glycosylceramide enthalten - Google Patents

Nkt-zellenaktivatoren, die alpha-glycosylceramide enthalten

Info

Publication number
ATE421881T1
ATE421881T1 AT04030878T AT04030878T ATE421881T1 AT E421881 T1 ATE421881 T1 AT E421881T1 AT 04030878 T AT04030878 T AT 04030878T AT 04030878 T AT04030878 T AT 04030878T AT E421881 T1 ATE421881 T1 AT E421881T1
Authority
AT
Austria
Prior art keywords
nkt cell
glycosylceramide
containing alpha
cell activators
activators containing
Prior art date
Application number
AT04030878T
Other languages
English (en)
Inventor
Masaru Taniguchi
Tetsu Kawano
Yasuhiko Koezuka
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of ATE421881T1 publication Critical patent/ATE421881T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
AT04030878T 1997-04-10 1998-04-10 Nkt-zellenaktivatoren, die alpha-glycosylceramide enthalten ATE421881T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9241297 1997-04-10

Publications (1)

Publication Number Publication Date
ATE421881T1 true ATE421881T1 (de) 2009-02-15

Family

ID=14053712

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04030878T ATE421881T1 (de) 1997-04-10 1998-04-10 Nkt-zellenaktivatoren, die alpha-glycosylceramide enthalten
AT98912758T ATE286735T1 (de) 1997-04-10 1998-04-10 Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98912758T ATE286735T1 (de) 1997-04-10 1998-04-10 Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten

Country Status (13)

Country Link
US (2) US6531453B1 (de)
EP (2) EP1520583B1 (de)
JP (1) JP3495740B2 (de)
KR (1) KR100527950B1 (de)
CN (2) CN1768759A (de)
AT (2) ATE421881T1 (de)
CA (1) CA2286482C (de)
DE (2) DE69828603T2 (de)
ES (2) ES2235324T3 (de)
HK (1) HK1029526A1 (de)
ID (1) ID23495A (de)
TW (1) TW592703B (de)
WO (1) WO1998044928A1 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW592703B (en) * 1997-04-10 2004-06-21 Kirin Brewery NKT cell-activating agents containing alpha-glycosylceramides
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
FR2792205B1 (fr) * 1999-04-19 2001-07-27 Inst Nat Sante Rech Med Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
SE0000258D0 (sv) 2000-01-27 2000-01-27 A & Science Invest Ab Pharmaceutical preparation and method for treatment of diabetes
US20010051156A1 (en) * 2000-04-28 2001-12-13 Defu Zeng Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions
CN1444648A (zh) * 2000-06-06 2003-09-24 麒麟麦酒株式会社 扩增自然杀伤t细胞的方法
AU2001268564A1 (en) * 2000-06-22 2002-01-02 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
JPWO2002038146A1 (ja) * 2000-11-07 2004-03-11 株式会社林原生物化学研究所 粘膜免疫調節剤並びにその用途
WO2002076401A2 (en) 2001-03-26 2002-10-03 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
CA2459482C (en) * 2001-08-16 2010-09-28 Daiichi Suntory Pharma Co., Ltd. Novel glycolipid and medicine for autoimmune disease containing the same as active ingredient
WO2003042377A1 (en) * 2001-11-07 2003-05-22 Kirin Beer Kabushiki Kaisha Expansion of t cells in vitro and expanded t cell populations
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
FR2839310A1 (fr) * 2002-05-03 2003-11-07 Pasteur Institut Nouveau procede de preparation d' alpha-glycosylceramides, nouveaux derives alpha-glycosylceramide et leurs applications
CA2493690C (en) * 2002-06-13 2011-11-08 New York University Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
US20060116331A1 (en) * 2002-09-27 2006-06-01 Biomira, Inc. Glycosylceramide analogues
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
DE602004020316D1 (de) 2003-01-20 2009-05-14 Tno Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma.
EP2343306B1 (de) * 2003-02-14 2018-04-04 Japan as represented by President of National Center of Neurology and Psychiatry Ministry of Health Glykolipidderivate, Herstellungsverfahren dafür, Zwischenprodukte für ihre Synthese und Herstellungsverfahren für die Zwischenprodukte
US20040171522A1 (en) * 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
US9717754B2 (en) 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20060239979A1 (en) * 2003-03-03 2006-10-26 Kirin Beer Kabushiki Kaisha Dendritic cell presenting a-glycosylceramide derivative and antigent and usable in suppressing immune response
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
US7771726B2 (en) * 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
WO2005079813A1 (ja) * 2004-02-19 2005-09-01 Kibun Food Chemifa Co., Ltd. Ｎｋｔ細胞活性化用組成物
EP1576894A1 (de) * 2004-03-16 2005-09-21 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Verwendung von Sphingolipiden zur Behandlung und Prävention von TYP 2 DIABETES, Insulinresistenz und METABOLISCHEN SYNDROMS
DE602005026785D1 (de) * 2004-03-16 2011-04-21 Tno Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom
JP2007531768A (ja) * 2004-03-31 2007-11-08 ニューヨーク・ユニバーシティ 感染症、癌および自己免疫疾患を治療するための新規な合成ｃ−糖脂質、その合成および使用
CA2569590C (en) * 2004-06-11 2014-04-01 Riken Drug having regulatory cell ligand contained in liposome
NZ553320A (en) * 2004-08-27 2011-02-25 Einstein Coll Med Ceramide derivatives as modulators of immunity and autoimmunity
US8022043B2 (en) * 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
EP1786439B1 (de) * 2004-09-03 2010-04-14 The University Of Chicago Verfahren zur aktivierung von nkt-zellen
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
EP1809737B9 (de) * 2004-10-07 2011-10-05 Argos Therapeutics, Inc. Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
PT1812015E (pt) 2004-11-02 2012-02-20 Univ Leland Stanford Junior Métodos de inibição de células nkt
EP1830829B1 (de) 2004-11-30 2012-01-04 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Sphingolipide bei der behandlung und prävention von hepatischer steatose
US7923013B2 (en) 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
CA2591232C (en) * 2004-12-28 2014-10-21 The Rockefeller University Glycolipids and analogues thereof as antigens for nk t cells
AU2006211485B2 (en) 2005-01-28 2011-04-14 Brigham Young University Bacterial glycolipid activation of CD1d-restricted NKT cells
WO2006093352A1 (ja) 2005-03-04 2006-09-08 Riken 環状構造を有する化合物及びその用途
WO2006107097A1 (ja) * 2005-04-01 2006-10-12 Riken 経鼻ワクチン
BRPI0612732A2 (pt) * 2005-07-01 2011-08-16 Japan As Represented By The President Of Nat Ct Of Neurology And Psychiatry derivado de glicolipìdeo e uso do mesmo
JP2007070311A (ja) * 2005-09-09 2007-03-22 Gunma Univ α−ガラクトシルセラミドからなる感染症予防剤及び感染症治療剤
US20090117089A1 (en) * 2005-09-19 2009-05-07 The Rockefeller University Glycolipids and analogues thereof as antigens for nk t cells
EP1945651B1 (de) 2005-10-25 2014-06-25 The Ludwig Institute for Cancer Research Analoge von alpha-galactosylceramid und anwendungen davon
US20090048185A1 (en) * 2005-10-28 2009-02-19 Sachiko Miyake Therapeutic Drug for Suppressing Functions of NKT Cells Containing Glycolipid Derivative as Active Ingredient
US20070231344A1 (en) * 2005-10-28 2007-10-04 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
US8163705B2 (en) * 2006-02-28 2012-04-24 Riken Glycolipid and use thereof
AU2007234753B2 (en) 2006-04-07 2013-02-21 Brigham Young University Modified -galactosyl ceramides for staining and stimulating Natural Killer T cells
IL178821A0 (en) * 2006-05-25 2007-07-04 Ilan Yaron Direct and indirect modulation of composition and structure of cell membrane by ??-glycolipids
JP5564672B2 (ja) * 2006-06-30 2014-07-30 ザ スクリプス リサーチ インスティテュート アジュバント及びその使用方法
US8263576B2 (en) * 2006-08-15 2012-09-11 Mayo Foundation For Medical Education And Research Non-natural sphingolipid analogs and uses thereof
KR100868959B1 (ko) 2006-12-30 2008-11-17 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는면역보조용 약학적 조성물
EP2112930B1 (de) 2007-02-21 2017-01-11 Vaccinex, Inc. Modulation der nkt-zellaktivität mit antigenbeladenen cdid-molekülen
ES2561357T3 (es) * 2007-02-22 2016-02-25 Riken Nuevo pseudoglucolípido y uso del mismo
US8916164B2 (en) 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2058011A1 (de) 2007-11-07 2009-05-13 Wittycell NKT-Zellen aktivierende, kovalent gebundene Glykolipid-Antigene und/oder Arzneimittel
EP2060252A1 (de) 2007-11-19 2009-05-20 Wittycell Neue Formulierung von Galactosylceramid-Derivaten
ES2525127T3 (es) 2007-12-05 2014-12-17 Abivax Utilización de las glicosilceramidas para aumentar la respuesta inmunitaria a los antígenos
WO2009119692A1 (ja) * 2008-03-25 2009-10-01 独立行政法人理化学研究所 新規糖脂質及びその用途
US9220767B2 (en) 2008-10-08 2015-12-29 Abivax Vaccine composition for use against influenza
DK2385980T3 (en) * 2009-01-08 2018-07-30 Albert Einstein College Medicine Inc BACTERIA VACCINES WITH CELL-WALL-ASSOCIATED CERAMIDE-LIKE GLYCOLIPIDS AND APPLICATIONS THEREOF
EP2532671B1 (de) 2010-02-05 2014-09-17 Riken Neues synthetisches glycolipid und verwendung davon
WO2011112889A2 (en) 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services β-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY
EP2647384B1 (de) 2010-12-02 2018-05-23 Riken IMMUNTHERAPIE MIT ALLO-NKT-ZELLEN, ZELLEN FÜR DIE IMMUNTHERAPIE MIT UMGEORDNETER aplha KETTE DES T-ZELL REZEPTOR (TCR)-GENS IN GLEICHMÄSSIGE V alpha-J alpha-ANORDNUNG UND LAGERUNG VON NKT-ZELLEN AUS DIESEN ZELLEN
KR102099764B1 (ko) 2012-04-26 2020-04-10 리가가쿠 겐큐쇼 신규 카르바메이트 당지질 및 그 용도
WO2014030708A1 (ja) 2012-08-22 2014-02-27 株式会社レグイミューン I型糖尿病の予防又は治療のための製剤
EP2903622A1 (de) * 2012-10-03 2015-08-12 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzungen zur prophylaktischen behandlung von bakteriellen superinfektionen nach einer influenza mit invarianten nkt-zellagonisten
EP2915535A4 (de) 2012-11-05 2016-08-24 Regimmune Corp Immuntoleranzinduktor
WO2014079946A1 (en) 2012-11-21 2014-05-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining the risk of acute graft versus host disease
CN105339379B (zh) 2013-02-08 2019-11-26 瓦克纳斯有限公司 改性的糖脂及其制备和使用方法
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
EP2993182B1 (de) 2013-05-02 2020-10-14 National Institute of Advanced Industrial Science and Technology Immunitätsinduzierer für saccharidantigene
US20170029454A1 (en) * 2013-06-28 2017-02-02 The Scripps Research Institute Nkt cell ligands and methods of use
JP6494594B2 (ja) * 2014-02-26 2019-04-03 国立大学法人北海道大学 樹状細胞を含有する医薬およびその製造方法
WO2017040885A1 (en) 2015-09-03 2017-03-09 The Board Of Regents Of The University Of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
WO2017163808A1 (ja) 2016-03-22 2017-09-28 学校法人慶應義塾 化合物又はその塩、ナチュラルキラーｔ細胞活性化剤、及び医薬組成物
WO2017207040A1 (en) 2016-06-01 2017-12-07 Vib Vzw ANTI-CANCER THERAPY USING A LEPTIN ANTAGONIST AND AN iNKT-CELL ACTIVATOR
CN106983760A (zh) * 2017-05-29 2017-07-28 南京佰泰克生物技术有限公司 一种增强肺腺癌细胞对cik细胞杀伤敏感性的组合物
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
AU2021392472A1 (en) 2020-12-04 2023-07-06 Osaka University Cd1d-ligand-compound-containing liposome preparation having improved pharmacokinetics
CN114196629B (zh) * 2021-12-23 2024-02-27 珠海贝索细胞科学技术有限公司 一种高效培养nkt细胞的试剂及其应用和nkt细胞的培养方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK84691D0 (da) * 1991-05-07 1991-05-07 Karsten Buschard Visse glycolipider og specifikke catchere for disse til anvendelse ved profylaxe eller terapi af diabetes, og/eller dermed forbundne komplikationer samt anvendelse af saadanne glycolipider til detektion af oe-celle-antistoffer (ica) i et individ og anvendelse af saadanne catchere til detektion af langerhans-oe-celler i pancreas-praeparater
TW261533B (de) * 1992-07-16 1995-11-01 Kirin Brewery
DE69328435T2 (de) * 1992-10-22 2000-09-14 Kirin Beer K.K., Tokio/Tokyo Neues sphingolglycolipid und verwendung davon
JPH06199884A (ja) * 1992-12-28 1994-07-19 Nisshin Oil Mills Ltd:The 新規糖脂質誘導体
WO1994024142A1 (en) * 1993-04-15 1994-10-27 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
JPH1045603A (ja) * 1996-07-30 1998-02-17 Yoshitomi Pharmaceut Ind Ltd スルファチドを有効成分とするＴＮＦ−α産生抑制剤
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
TW592703B (en) * 1997-04-10 2004-06-21 Kirin Brewery NKT cell-activating agents containing alpha-glycosylceramides

Also Published As

Publication number Publication date
CN1222293C (zh) 2005-10-12
DE69840528D1 (de) 2009-03-19
EP0988860B1 (de) 2005-01-12
WO1998044928A1 (en) 1998-10-15
US6747010B2 (en) 2004-06-08
AU6748598A (en) 1998-10-30
DE69828603T2 (de) 2005-12-29
ATE286735T1 (de) 2005-01-15
ES2318236T3 (es) 2009-05-01
US6531453B1 (en) 2003-03-11
CN1259872A (zh) 2000-07-12
DE69828603D1 (de) 2005-02-17
CA2286482C (en) 2008-08-05
ID23495A (id) 2000-04-27
EP0988860A4 (de) 2003-09-03
AU742253B2 (en) 2001-12-20
EP1520583A3 (de) 2006-01-25
TW592703B (en) 2004-06-21
HK1029526A1 (en) 2001-04-06
JP3495740B2 (ja) 2004-02-09
ES2235324T3 (es) 2005-07-01
EP0988860A1 (de) 2000-03-29
US20030139351A1 (en) 2003-07-24
KR100527950B1 (ko) 2005-11-09
EP1520583B1 (de) 2009-01-28
EP1520583A2 (de) 2005-04-06
CN1768759A (zh) 2006-05-10
CA2286482A1 (en) 1998-10-15
KR20010006174A (ko) 2001-01-26

Similar Documents

Publication Publication Date Title
ATE421881T1 (de) Nkt-zellenaktivatoren, die alpha-glycosylceramide enthalten
DE69110625D1 (de) Oxazolopyridinderivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen.
ATE71625T1 (de) Imidazoheterocyclische verbindungen, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
EP0508488A3 (de) Verwendung von Inositoltriphosphat zur Behandlung von mit Metallvergiftungen verbundenen Krankheiten
IL109615A0 (en) Polypeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
ES2089665T3 (es) Terazosina polimorfa y composicion farmaceutica.
ATE38991T1 (de) In 2-stellung substituierte 1,3propyledendephosphonat-derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
ES8102561A1 (es) Procedimiento de preparacion de los aril-1 arilsulfonil-4 a amino-propoxi-3 1h pirazoles
ES8106302A1 (es) Un procedimiento para la preparacion de derivados de acido trans-(4-oxo-4h-quinazolin-3-il)-2-propenoico
AU6428001A (en) Vitamin d derivatives
DE60032470D1 (de) Heilmittel die sulfopyranosylacylglycerolderivate enthalten
ES2103440T3 (es) Nuevas amidas y sulfonamidas naftalenicas, procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ATE84035T1 (de) Antivirale tetrahydroimidazo(1,4)benzodiazepin-2- one.
AU626743B2 (en) Therapeutic application of fluoroquinolone derivatives for pneumocystosis
IL107614A0 (en) Vitamin d3 analogs their preparation and pharmaceutical compositions containing them
ES2057802T3 (es) Nuevos derivados de 3-amino-cromano, procedimiento de preparacion y composiciones farmaceuticas que los contienen.
AU6250680A (en) Phosphono-hydroxy-acetic acid
ES8500269A1 (es) Procedimiento para la fabricacion de un derivado de azolcarboxamida n,n-subsitutida.
DE69414396D1 (de) Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten
ATE86117T1 (de) Zusammensetzung gegen leberkrankheiten.
EP0666253A4 (de) N-t-BUTYLANILIN ANALOGE VERBINDUNGEN ALS LIPIDLEVEL-SENKER.
FI872997A (fi) Amidderivat.
FR2355846A1 (fr) Esters de penicillines utilisables comme medicaments
DE69307414D1 (de) Dipeptidderivate und diese als aktive Bestandteile enthaltendes prophylaktisches oder therapeutisches Mittel gegen Knochenkrankheiten
ES465545A1 (es) Procedimiento para la preparacion de esteres tiolicos del acido amidinofosdorico

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties